2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Survival Benefit? What Are the Response Rates With Teclistamab?
By
Nebraska Oncology Society
FEATURING
Adam D. Cohen
By
Nebraska Oncology Society
FEATURING
Adam D. Cohen
Login to view comments.
Click here to Login